Drug Discovery · New York, NY · Founded 2019 · Privately Held (backing)
Developer of virus-resistant live bacterial products designed to modulate the human microbiome. Ancilia Bio is based in New York, NY and was founded in 2019. It was valued at $28 million at its seed round in Apr 2026, the last priced event on record. It has raised $11.1 million across 1 recorded round; the latest was an early-stage round in Apr 2023.
PMV mark · valuation
$28.0M
Oct 2026
Priced at
its seed round
Apr 2026
Total raised
$11.1M
Last round
Early Stage VC
Apr 2023
Team — not yet on record
No current team members for Ancilia Bio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ancilia Bio with a free account
·The complete investor list: 13 names
·Watch Ancilia Bio: the Monday email on marks, rounds and moves
